These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38566987)

  • 21. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
    Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
    Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
    Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment options for mantle cell lymphoma.
    Smolewski P; Witkowska M; Robak T
    Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.
    Chan WK; Williams J; Sorathia K; Pray B; Abusaleh K; Bian Z; Sharma A; Hout I; Nishat S; Hanel W; Sloan SL; Yasin A; Denlinger N; Zhang X; Muthusamy N; Vasu S; de Lima M; Yang Y; Baiocchi R; Alinari L
    Exp Hematol Oncol; 2023 Sep; 12(1):79. PubMed ID: 37740214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
    Munoz JL; Wang Y; Jain P; Wang M
    Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.
    Gauthier J; Maloney DG
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):957-970. PubMed ID: 32861289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis.
    Le K; Sun J; Khawaja H; Shibata M; Maggirwar SB; Smith MR; Gupta M
    Blood Adv; 2021 Jul; 5(14):2863-2878. PubMed ID: 34297045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of thalidomide and lenalidomide in mantle cell lymphoma.
    Richardson SJ; Eve HE; Copplestone JA; Dyer MJ; Rule SA
    Acta Haematol; 2010; 123(1):21-9. PubMed ID: 19907157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The application of HER2 and CD47 CAR-macrophage in ovarian cancer.
    Chen Y; Zhu X; Liu H; Wang C; Chen Y; Wang H; Fang Y; Wu X; Xu Y; Li C; Lv X; Huang J; Han X; Li R; Hong W; Yu Z; Wei W; Tu J
    J Transl Med; 2023 Sep; 21(1):654. PubMed ID: 37740183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular Therapies for Mantle Cell Lymphoma.
    Yassine F; Sandoval-Sus J; Ayala E; Chavez J; Hamadani M; Kharfan-Dabaja MA
    Transplant Cell Ther; 2021 May; 27(5):363-370. PubMed ID: 33965173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
    Tbakhi B; Reagan PM
    Ther Adv Hematol; 2022; 13():20406207221080738. PubMed ID: 35237395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.
    Chiron D; Bellanger C; Papin A; Tessoulin B; Dousset C; Maiga S; Moreau A; Esbelin J; Trichet V; Chen-Kiang S; Moreau P; Touzeau C; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Blood; 2016 Dec; 128(24):2808-2818. PubMed ID: 27697772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.
    Sakakura K; Takahashi H; Kaira K; Toyoda M; Murata T; Ohnishi H; Oyama T; Chikamatsu K
    Lab Invest; 2016 Sep; 96(9):994-1003. PubMed ID: 27322955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
    Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
    Front Immunol; 2022; 13():929339. PubMed ID: 36389667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in genomics and therapeutics in mantle cell lymphoma.
    Lu T; Zhang J; McCracken JM; Young KH
    Cancer Treat Rev; 2024 Jan; 122():102651. PubMed ID: 37976759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
    Cai F; Zhang J; Gao H; Shen H
    Eur J Haematol; 2024 Feb; 112(2):223-235. PubMed ID: 37706523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.